OncoMatch/Clinical Trials/NCT04468841
Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma
Is NCT04468841 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for follicular lymphoma.
The researchers are doing this study to measure and test cell-free DNA (cfDNA) in the blood before, during, and after first-line treatment for follicular lymphoma. They will look at whether cfDNA levels are related to a person's response to the usual first-line treatment for follicular lymphoma. Researchers also want to understand how different genetic changes in follicular lymphoma relate to a person's response to the usual first-line treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Prior therapy
Cannot have received:
Exception: retrospective cohort of long-term survivors of FL [i.e. >10 years out from frontline treatment]
Patients receiving second or greater line of therapy (except in retrospective cohort of long-term survivors of FL [i.e. >10 years out from frontline treatment])
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Monmouth (All protocol activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Commack (All Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (All Protocol Activities) · Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify